Former CEO of Susan G. Komen Brings Health Policy, Operational Expertise to Board Leadership
NASHVILLE, Tenn., April 18, 2017 – Pierian Biosciences, the premier developer of life science technologies providing treatment-directing data to aid physicians in selecting the most appropriate therapy for their patients with cancer, has named Dr. Judith Salerno to its board of directors.
“Judy has been a steadfast leader in the development of health care policy and in the operational implementation of those strategies in many clinical institutions,” says Robert Henry, president and chief executive officer of Pierian Biosciences. “We are delighted she has agreed to join us as a member of our board.”
As president and CEO of Susan G. Komen, a $200 million breast cancer awareness and advocacy organization, Dr. Salerno developed and implemented a new strategic vision for Susan G. Komen. The “More Than Pink” campaign broadened the organization’s reach to include everyone impacted by the disease.
Prior to joining Susan G. Komen, she was the executive officer at the Institute of Medicine, where she directed all scientific, policy, and operational efforts. She has also served as the deputy director of the National Institute on Aging, responsible for oversight of their $1B budget on aging research, as well as chief geriatric policy consultant for the Department of Veterans Affairs.
A graduate of Harvard Medical School and Harvard University School of Public Health, Dr. Salerno is certified in the Commonwealth of Virginia and the District of Columbia. She is the recipient of many awards, including the NIH Director’s Award, Department of Veterans Affairs Exemplary Service Award and its highest award, the Meritorious Service Award, and the Surgeon General’s Crisis Response Service Award. She is currently active in Palliative Care and Health Policy issues through her work with the National Academy of Medicine, USC Schaeffer Center, and the Lancet Commission.
About Pierian Biosciences
Based in Franklin, Tenn., Pierian Biosciences is a privately held life sciences company offering the development and delivery of innovative, treatment-directing information, allowing providers to design patient-specific strategies that improve outcomes, quality of life and lower the cost of cancer care. The company’s technology includes the ChemoINTEL, ImmunoINTEL and PathwayINTEL platforms. Pierian Biosciences has laboratories in Franklin, Tenn. and San Diego, CA and business offices in Franklin, Tenn and the UK. For more information visit http://pierianbio.com.